Order of the President of the General Court of 18 October 2022 – Fresenius Kabi Austria and Others v Commission

(Case T-416/22 R)

(Interim relief – Medicinal products for human use – Directive 2001/83/EC – Marketing authorisations for medicinal products containing the active substance ‘hydroxyethyl starch (HES), solutions for infusion’ – Application for suspension of operation of a measure – No urgency)

Language of the case: English

Parties

Applicants: Fresenius Kabi Austria GmbH (Graz, Austria), and the 14 other applicants whose names are listed in the annex to the order (represented by: W. Rehmann and A. Knierim, lawyers)

Defendant: European Commission (represented by: M. Escobar Gómez and K. Mifsud-Bonnici, acting as Agents)

Re:

By their application under Articles 278 and 279 TFEU, the applicants seek the suspension of operation of European Commission Implementing Decision C(2022) 3591 final of 24 May 2022 concerning, in the framework of Article 107p of Directive 2001/83/EC of the European Parliament and of the Council, the marketing authorisations of medicinal products for human use which contain the active substance ‘hydroxyethyl starch (HES), solutions for infusion’ following an assessment of a post authorisation safety study.

Operative part of the order

The application for interim measures is dismissed.

2.    The costs are reserved.

____________